Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
2.
Radiol Med ; 115(8): 1267-78, 2010 Dec.
Article in English, Italian | MEDLINE | ID: mdl-20680499

ABSTRACT

PURPOSE: We report a preliminary evaluation of the performance of computed tomography colonography (CTC) systematically obtained before optical colonoscopy (OC) in subjects with positive faecal occult blood test (FOBT) within a population-based screening programme for colorectal cancer (CRC). MATERIALS AND METHODS: Seventy-nine subjects with positive FOBT from a regional screening programme were invited to perform same day CTC and OC. CTC was performed with standard bowel preparation. OC with segmental unblinding was the reference standard. A per-patient per-adenoma analysis was performed. RESULTS: Forty-nine of 79 subjects (62%) with positive FOBT adhered to the study and completed both examinations. Twenty-two (44.9%) of the 49 had a cancer or an adenoma ≥6 mm. Per-patient sensitivity, specificity, negative predictive value and positive predictive value for cancer or adenoma ≥6 mm were 95.5% (95%CI:77.2%-99.9%), 51.9% (95%CI:32.0%-71.3%), 93.3% (95%CI:68.1%-99.8%) and 61.8% (95%CI:43.6%-77.8%). CONCLUSIONS: In the setting of a FOBT-based screening programme for CRC, CTC showed a high sensitivity, but relatively low specificity and positive predictive value, for cancer and adenoma ≥6 mm. Probably performing CTC without faecal tagging as second line test after a positive FOBT is not a cost-effective strategy.


Subject(s)
Colonography, Computed Tomographic/methods , Colorectal Neoplasms/diagnostic imaging , Mass Screening , Aged , Colonoscopy , Colorectal Neoplasms/diagnosis , Colorectal Neoplasms/epidemiology , Female , Humans , Italy/epidemiology , Male , Middle Aged , Occult Blood , Predictive Value of Tests , Prospective Studies , Radiographic Image Interpretation, Computer-Assisted , Sensitivity and Specificity
3.
Recenti Prog Med ; 87(10): 476-9, 1996 Oct.
Article in Italian | MEDLINE | ID: mdl-9026853

ABSTRACT

We describe a case of essential thrombocythemia observed in a 67-year-old woman with severe IgA-deficiency. The the best of our knowledge, this is the first report concerning the onset of a chronic myeloproliferative disease (CMPD) in a patient affected with primary immunodeficiency, in particular IgA-defect. The association may be merely coincidental; otherwise hemopoietic growth factors acting on myeloid progenitor cells could play a role in this relationship. It has recently been shown that serum levels of many cytokines are elevated in patients with CMPD and probably contribute to enhance proliferation of the malignant clones; on the other hand interleukin-6 seems to account for reactive thrombocytosis, and significant amounts of circulating interleukin-4 and interleukin-6 have been detected in IgA-deficient patients. Overproduction of the two cytokines may depend on recurrent infections, but it could also represent a primary abnormality, with a putative role in the pathogenesis of the immune defect. These findings suggest that high levels of growth factors could induce myeloid hyperproliferation and so expose stem cells to genetic mutations responsible for malignant transformation.


Subject(s)
IgA Deficiency/diagnosis , Thrombocythemia, Essential/diagnosis , Aged , Aspirin/therapeutic use , Bacterial Vaccines/therapeutic use , Biopsy , Bone Marrow/pathology , Chronic Disease , Combined Modality Therapy , Female , Humans , IgA Deficiency/complications , IgA Deficiency/therapy , Immunoglobulins/blood , Platelet Count , Thrombocythemia, Essential/etiology , Thrombocythemia, Essential/therapy
4.
Minerva Med ; 81(1-2): 99-102, 1990.
Article in Italian | MEDLINE | ID: mdl-2314622

ABSTRACT

The case is reported of a patient with polycythemia vera, who developed an anterior panhypopituitarism, due to an adenoma, some years later. The endocrine deficiency caused the return of the hemoglobin count and global red cell volume to the normal range. The finding suggests that in polycythemia vera the neoplastic growth is still partially responsive to normal hemoregulator factors.


Subject(s)
Adenoma/complications , Erythropoietin/analysis , Hematopoiesis , Pituitary Neoplasms/complications , Polycythemia Vera/etiology , Adenoma/diagnostic imaging , Adenoma/physiopathology , Aged , Hemoglobins/analysis , Humans , Male , Pituitary Neoplasms/diagnostic imaging , Pituitary Neoplasms/physiopathology , Polycythemia Vera/blood , Polycythemia Vera/physiopathology , Tomography, X-Ray Computed
7.
Psychiatry Res ; 20(1): 19-31, 1987 Jan.
Article in English | MEDLINE | ID: mdl-2951760

ABSTRACT

Clinical and biochemical findings link anorexia nervosa (AN) and primary effective disorders (PAD). Clonidine, an alpha 2-adrenoceptor agonist, has been shown to blunt growth hormone (GH) response and greatly lower plasma cortisol in PAD patients. We examined the GH, cortisol, and beta-endorphin (beta-EP) responses to an acute clonidine challenge (150 micrograms i.v. as a bolus) before and after 30 days of treatment with desmethylimipramine in 14 women with AN. Both before and after treatment, the AN patients showed normal plasma GH and cortisol responses, but an increased plasma beta-EP response. The increased beta-EP response in AN was independent of weight and depressive symptomatology. Our data indicate that alpha 2-adrenoceptors involved in the control of GH and adrenocorticotropic hormone are not altered in AN. The increased beta-EP response may indicate elevated opioid activity in the hypothalamo-pituitary system of AN patients.


Subject(s)
Anorexia Nervosa/blood , Clonidine , Endorphins/blood , Growth Hormone/blood , Hydrocortisone/blood , Adolescent , Adult , Anorexia Nervosa/diagnosis , Anorexia Nervosa/drug therapy , Desipramine/therapeutic use , Female , Humans , beta-Endorphin
8.
Psychiatry Res ; 16(2): 165-76, 1985 Oct.
Article in English | MEDLINE | ID: mdl-2933758

ABSTRACT

Clinical and biochemical data suggest a link between anorexia nervosa (AN) and primary affective disorders (PAD). In 14 female patients, aged 15-40 years, with 7-month to 11-year histories of AN, we studied circadian cortisol periodicity, response to the dexamethasone suppression test (DST), and plasma levels of beta-endorphin and beta-lipotropin before and after desimipramine therapy. Possible correlations were sought among neuroendocrine impairments, weight loss, and depressive symptomatology. Impaired circadian cortisol periodicity, blunted DST response, and increased beta-endorphin plasma levels, observed in a subgroup of patients, could not be related to weight loss, either before or after therapy. Instead, a trend toward a relationship between neuroendocrine impairments and depressive symptoms was observed before and after treatment.


Subject(s)
Anorexia Nervosa/drug therapy , Desipramine/therapeutic use , Adolescent , Adult , Affective Disorders, Psychotic/physiopathology , Affective Disorders, Psychotic/psychology , Anorexia Nervosa/physiopathology , Anorexia Nervosa/psychology , Dexamethasone , Endorphins/blood , Female , Humans , Hydrocortisone/blood , Hypothalamo-Hypophyseal System/physiopathology , beta-Endorphin , beta-Lipotropin/blood
9.
Psychiatry Res ; 13(4): 295-304, 1984 Dec.
Article in English | MEDLINE | ID: mdl-6097932

ABSTRACT

Neuroendocrine effects of intravenous injections of clonidine, 0.15 mg, were investigated in 13 heroin addicts and 14 normal control subjects. The study was designed to determine whether continuous opiate administration leads to the development of hypersensitive alpha 2-adrenergic receptors. The peak increments in levels of plasma growth hormone (GH) and beta-endorphin induced by clonidine did not differ between heroin addicts and normal control subjects. At no time interval could the clonidine-induced rise in GH levels in addicts be differentiated from that induced by placebo. Clonidine failed to alter plasma prolactin, gonadotropin, or thyrotropin levels in either heroin addicts or controls. Since clonidine's neuroendocrine effects are reportedly due to the activation of postsynaptic alpha 2-adrenoceptors, it appears that (1) continuous opiate use does not lead to the development of hypersensitive alpha 2-adrenergic receptors involved in neuroendocrine mechanisms and (2) brain norepinephrine does not play a role in the regulation of tonic prolactin, gonadotropin, and thyrotropin secretion in man.


Subject(s)
Clonidine , Heroin Dependence/blood , Pituitary Hormones, Anterior/blood , Adolescent , Adult , Endorphins/blood , Female , Follicle Stimulating Hormone/blood , Growth Hormone/blood , Humans , Luteinizing Hormone/blood , Male , Prolactin/blood , Receptors, Adrenergic/drug effects , Thyrotropin/blood , beta-Endorphin
11.
Acta Endocrinol (Copenh) ; 103(3): 315-20, 1983 Jul.
Article in English | MEDLINE | ID: mdl-6880568

ABSTRACT

Cirrhotic patients reportedly show alterations of anterior pituitary hormone secretion, which may reflect an underlying defective central neurotransmitter function. In this study, we have investigated the catecholaminergic control of prolactin (Prl) and growth hormone (GH) secretion in cirrhotic patients by means of an indirectly acting dopamine (DA) and norepinephrine agonist, nomifensine (Nom), and a DA receptor antagonist, domperidone (Dom). Basal GH levels were higher in the 12 female and male cirrhotic patients than in the 12 age- and sex-matched normal controls, while no difference was present in basal Prl values. Administration of Nom (200 mg po) suppressed basal Prl levels (at least 30% inhibition at three consecutive times post-drug administration) in 6/12 controls and in 6/12 cirrhotic patients, the frequency of negative responses not being different between the two groups. Nom induced a slight elevation of GH levels in controls, and evoked a more marked and sustained GH increase in cirrhotic patients. Administration of Dom (4 mg iv) induced similar Prl increments in 6 male controls and 6 male cirrhotic patients. Normal Prl responsiveness to Nom and Dom points to the existence of preserved tubero-infundibular DA function and modulation of pituitary DA receptors in the cirrhotic patients investigated. Higher GH responsiveness to Nom is compatible with a different bioavailability of the drug.


Subject(s)
Domperidone/pharmacology , Growth Hormone/metabolism , Isoquinolines/pharmacology , Liver Cirrhosis, Alcoholic/physiopathology , Nomifensine/pharmacology , Prolactin/metabolism , Receptors, Dopamine/drug effects , Adult , Female , Humans , Hypothalamus/drug effects , Liver Cirrhosis, Alcoholic/blood , Male , Middle Aged , Pituitary Gland, Anterior/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...